EUVIMEDEUVIMED entdecken
Crossref

RPS17 can act as a tumor suppressive ribosomal protein in human cell lines

Takuya Takafuji, Yukino Mori, Natsuka Tsutsui, Natsumi Yanagi, Tohru Kiyono, Hidetaka Kosako iD, Yoko Katsuki, Nozomi Sugimoto, Masatoshi Fujita iD

The Journal of Biochemistry · 05.11.2026

DOI: 10.1093/jb/mvag083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Biochemistry, online erschienen am 05.11.2026. Verfasst von Takuya Takafuji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Jap….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Certain ribosomal proteins (RPs) function as tumor suppressors. For example, RPL5 and RPL11 suppress oncogenesis by binding to MDM2 and thereby up-regulating p53, a mechanism referred to as the RP-MDM2-p53 cascade. However, whether other cancer-associated ribosomal proteins actually function as tumor suppressors has remained largely unclear. Previously, we showed that siRNA-mediated silencing of RPS17, in combination with expression of HPV16 E7 and activated KRAS G12V, transformed normal human fibroblasts. Here, we expanded our study to perform a functional analysis of RPS17 as a tumor suppressor. We first demonstrate that shRNA-mediated RPS17 silencing also promotes oncogenic transformation of human fibroblasts in vitro and in vivo. Conversely, its overexpression inhibits the soft agar colony formation of colon cancer-derived HCT116 cells in a p53-dependent manner. RPS17 weakly interacts with MDM2. However, unlike RPL5 and RPL11, overexpression of RPS17 does not increase p53 levels and its silencing induces p53, suggesting that the RP-MDM2-p53 cascade might not be a major pathway for its tumor-suppressive function. We further show that RPS17 binds to nucleophosmin and modulates its nuclear localization. Although the detailed molecular mechanisms underlying the tumor-suppressive function of RPS17 remain to be elucidated, this study provides evidence that RPS17 can function as a tumor suppressor.

Schlagwörter

Stichwörter der Autor:innen

RPS17cancer-prone ribosomopathynucleophosminp53tumor-suppressive ribosomal proteins

Autor:innen und Institutionen

  • Department of Cellular Biochemistry, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
  • Project for Prevention of HPV-related Cancer, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
  • Division of Cell Signaling, Institute of Advanced Medical Sciences, Tokushima University, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan.
  • Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-ku, Tokyo 143-8540, Japan.

ORCID-Profile: Hidetaka Kosako, Masatoshi Fujita

Zitieren

APA

Takafuji, T., Mori, Y., Tsutsui, N., Yanagi, N., Kiyono, T., Kosako, H., Katsuki, Y., Sugimoto, N., & Fujita, M. (2026). RPS17 can act as a tumor suppressive ribosomal protein in human cell lines. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvag083

Vancouver

Takafuji T, Mori Y, Tsutsui N, Yanagi N, Kiyono T, Kosako H, et al. RPS17 can act as a tumor suppressive ribosomal protein in human cell lines. The Journal of Biochemistry. 2026. doi:10.1093/jb/mvag083

BibTeX
@article{Takafuji2026,
  author = {Takafuji, Takuya and Mori, Yukino and Tsutsui, Natsuka and Yanagi, Natsumi and Kiyono, Tohru and Kosako, Hidetaka and Katsuki, Yoko and Sugimoto, Nozomi and Fujita, Masatoshi},
  title = {RPS17 can act as a tumor suppressive ribosomal protein in human cell lines},
  journal = {The Journal of Biochemistry},
  year = {2026},
  doi = {10.1093/jb/mvag083}
}
Kostenlos starten →